Data collection included physical and lifestyle measures, personal and family history, measurement of haemoglobin, fasting glucose, creatinine, lipid panel and urinary albumin:creatinine ratio, a cognitive battery, mood and depression questionnaire, physical function measures (gait speed and grip strength), Katz activities of daily living, quality of life and clinical endpoint screening (death, dementia, disability, cancer, cardiovascular disease, depression and major haemorrhage) [19, 20]. This evidence concerns the gene ALB and depressive symptom measurement.